share_log

Stifel Maintains Buy on Deciphera Pharmaceuticals, Raises Price Target to $22

Benzinga ·  Oct 31, 2023 14:00

Stifel analyst Bradley Canino maintains Deciphera Pharmaceuticals (NASDAQ:DCPH) with a Buy and raises the price target from $20 to $22.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment